NeurogesX’s Qutenza Can’t Get Past 30 Minutes At Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
The specter of future drug sponsors with weak efficacy evidence besieging FDA helped persuade the Anesthetic and Analgesic Drug Products Advisory Committee to unanimously reject Qutenza (capsaicin 8%) patch for treatment of pain from HIV neuropathy.